Data investigation

When the Appetite Center Is Damaged

For people whose obesity follows damage to the brain's appetite center, almost nothing works. A study of 116 patients found modest average weight loss and something more important: 8% hospitalized for hormonal decompensation.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·3 citations

For people whose obesity comes from damage to the brain’s appetite center, usually after surgery or radiotherapy for a tumor near the pituitary, most treatments do little. The exception so far is setmelanotide, a daily injection whose label has covered this condition since March 2026.[2] For GLP-1 drugs, a study of 116 such patients found modest average weight loss and something more important: 8% were hospitalized for hormonal decompensation.[1]

Why this population is different

Craniopharyngioma is a benign tumor that grows near the pituitary gland and hypothalamus. Removing or irradiating it frequently damages the hypothalamus, the structure that regulates hunger, fullness, temperature and the hormonal axes beneath it. The result, acquired hypothalamic obesity, is relentless weight gain driven by a broken regulator rather than by behavior. It is a different mechanism from the cortisol excess behind obesity in Cushing’s syndrome.

Most of these patients also depend on replacement hormones taken by mouth: hydrocortisone for adrenal function, desmopressin for water balance, often thyroid hormone and others. That dependence is what makes the safety finding below specific to them.

The safety finding

Adverse events across 116 adults treated at 16 French obesity centers.[1]
EventProportion
Adrenal insufficiency decompensation12%
Vasopressin deficiency decompensation10%
Required hospitalization8%
Gastrointestinal intolerance leading to stopping13%
Adrenal crisis is a medical emergency and can be fatal. The mechanism here is not exotic: these drugs cause nausea and vomiting and reduce how much people eat and drink. Someone who depends on swallowing hydrocortisone every day, and cannot keep it down, loses their cortisol replacement. Someone on desmopressin whose fluid intake collapses loses control of their sodium. Neither risk exists for a person with an intact pituitary.

This is why a general statement that these drugs are well tolerated does not settle anything for a particular patient. The commonest side effect of the class is gut upset, mild and self-limiting in most people. In this population, that same side effect is how the drug becomes dangerous.

The authors’ conclusion follows directly: specific endocrine monitoring is essential. That is a concrete requirement, not a hedge.

The average is the wrong number

Over a mean follow-up of 44 months, average weight loss was −4.6%, with a standard deviation of 12.5.

The spread is nearly three times the average.

A distribution like that stretches from very large losses to substantial gains. The supporting figures confirm it: 51% of patients lost at least 5% of their weight and 28% lost at least 10%. Against a mean of only 4.6%, that means the remaining half did badly enough to pull the average down that far.

So “these drugs produce about 5% weight loss in hypothalamic obesity” is the wrong summary. Roughly half of patients responded usefully, a quarter responded well, and the rest did not respond or gained. Nobody can currently tell in advance which group someone will land in.

What responded better, within the study.[1]
ComparisonResult
Semaglutide (mean dose 1.2 mg/week)−6.8%, the largest of the drugs used
Semaglutide, patients without diabetes−8.5% (± 12.3) vs −3.9% (± 10.0) with diabetes, p = 0.032

That diabetes gap matches the pattern seen throughout this drug class, where type 2 diabetes reliably reduces weight response. Note the dose too: a mean of 1.2 mg per week is well below the 2.4 mg used for weight management, so this is a submaximal-dosing result.

What it does and does not establish

  • It is retrospective. Records from 16 centers, not a trial, with no control group.
  • It does not transfer to common obesity, and common obesity results do not transfer here. The regulator itself is damaged, which is a different disease.
  • The dosing was submaximal, so response at full dose is unknown, and so is whether the endocrine risk would rise with it.
  • Modest average benefit is still benefit in a condition with very few options, and half of patients reaching 5% is not nothing.

For anyone in this situation, the practical takeaway is the monitoring rather than the percentage: sick-day rules for steroid replacement, a plan for what to do when vomiting starts, and endocrine follow-up arranged before the first dose rather than after the first crisis.

The drug approved for this condition

Setmelanotide (Imcivree) is not a GLP-1. It is a melanocortin-4 receptor agonist, and FDA extended its label in March 2026 to people aged 4 and older with acquired hypothalamic obesity.[2] In the phase 3 TRANSCEND trial, 120 people aged 4 to 66 were assigned 2:1 to setmelanotide or placebo. At 52 weeks BMI had changed by −16.5% on the drug and +3.3% on placebo, and hunger scores fell further too.[3]

It has costs of its own. Serious adverse events were reported in 28% on setmelanotide against 8% on placebo, and skin darkening, nausea, vomiting and headache were the most common events. The manufacturer funded the trial. It also was not a comparison with GLP-1 drugs: it was randomized and the French study above was not, so the two sets of numbers cannot be set side by side.[3] Nausea and vomiting matter here for the same reason as above, so the endocrine plan is worth settling before the first dose of this drug too.

Frequently Asked Questions

Yes. Setmelanotide (Imcivree), which is not a GLP-1, gained the indication in March 2026 for people aged 4 and older. In its phase 3 trial, BMI changed by -16.5% against +3.3% on placebo at 52 weeks, with serious adverse events in 28% against 8%.
Modestly and inconsistently. Across 116 adults, average weight loss was 4.6% with a standard deviation of 12.5: 51% lost at least 5% and 28% at least 10%, while the rest did not respond or gained.
Hormonal decompensation. Adrenal insufficiency decompensated in 12% and vasopressin deficiency in 10%, with 8% requiring hospitalization. It happens because these drugs cause vomiting and reduce intake in people who depend on swallowing replacement hormones daily.
Because the standard deviation is nearly three times the mean, so the distribution runs from large losses to substantial gains. Half the patients reached 5% loss while the average sat at 4.6%, meaning the other half pulled it down.
Semaglutide, at a mean dose of 1.2 mg weekly, produced 6.8%, and 8.5% in patients without diabetes against 3.9% in those with it. That dose is well below the 2.4 mg used for weight management.
Endocrine monitoring, which the study's authors call essential. That includes a clear plan for steroid replacement during vomiting, made before starting rather than after a crisis.

References

  1. 1.Lambert F, Guillon E, Gatta-Cherifi B, et al. Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study Diabetes, Obesity and Metabolism. 2026. PMID: 41153084.
  2. 2.Rhythm Pharmaceuticals IMCIVREE (setmelanotide) injection: prescribing information (section 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9
  3. 3.Miller JL, van Santen HM, Phillips SA, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity New England Journal of Medicine. 2026. PMID: 42418774.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

8.1

Sesame Care

Oral orforglipron alongside the injectables

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →